# TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

> **NCT03680508** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Hawaii** · enrollment: 42 (actual)

## Conditions studied

- Adult Primary Liver Cancer
- Advanced Adult Primary Liver Cancer
- Localized Unresectable Adult Primary Liver Cancer

## Interventions

- **DRUG:** TSR-022 and TSR-042

## Key facts

- **NCT ID:** NCT03680508
- **Lead sponsor:** University of Hawaii
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-19
- **Primary completion:** 2026-03-06
- **Final completion:** 2027-10
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03680508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03680508, "TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03680508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*